<b>Methods:</b> Two established models of experimental colitis, namely chemically-induced DSS colitis and the spontaneous colitis that develops in <i>Muc2</i> deficient mice, were used to assess whether QBECO treatment could ameliorate gastrointestinal disease.
<b>Methods:</b> Two established models of experimental colitis, namely chemically-induced DSS colitis and the spontaneous colitis that develops in <i>Muc2</i> deficient mice, were used to assess whether QBECO treatment could ameliorate gastrointestinal disease.
<b>Methods:</b> Two established models of experimental colitis, namely chemically-induced DSS colitis and the spontaneous colitis that develops in <i>Muc2</i> deficient mice, were used to assess whether QBECO treatment could ameliorate gastrointestinal disease.
Secretin-stimulated pancreatic/duodenal juice from 15 individuals undergoing endoscopic investigation for upper gastrointestinal disease was also analyzed.
Lysozyme is an enzyme found in biological fluids, which is upregulated in leukemia, renal diseases as well as in a number of inflammatory gastrointestinal diseases.
Protease activated receptor 2 (PAR2) is associated with metabolism, obesity, inflammatory, respiratory and gastrointestinal disorders, pain, cancer, and other diseases.
COG6-CDG is a rare autosomal recessive disease of congenital disorders of glycosylation (CDG) caused by deficiency of subunit 6 of the conserved oligomeric Golgi complex (COG6), which is characterized by growth retardation, developmental disability, microcephaly, liver and gastrointestinal disease, recurrent infections and hypohidrosis/hyperthermia.
IL-22 is the most intensively studied cytokine within this family in contexts of gastrointestinal disease, but the importance of other family members is more and more appreciated.
Guanylate cyclase-C (GC-C) is a multifunctional receptor encoded by the <i>GUCY2C</i> gene, representing an attractive target for therapy in several gastrointestinal diseases in humans.
A combination therapy of pegylated interferon alfa-2a and ribavirin (PEG-IFNa/RBV) is a standard treatment, but the effect of this antiviral therapy needs evaluation as to determine the efficacy and safety of dual PEG-IFNa/RBV therapy in treating patients infected with HCV in Myanmar.This was a retrospective analysis of data from a single clinic exclusively for gastrointestinal diseases in Yangon, Myanmar.
According to our data, RDW was found to be a valuable prognostic index in gastrointestinal disorders along with additional inflammatory biomarkers (<i>i.e</i>., C reactive protein, erythrocyte sedimentation rate, and platelet count) and current disease severity indices used in clinical practice.
According to this survey, only a minor portion of the 44 medicinal plants considered in EMA monographs for the treatment of gastrointestinal diseases has been studied so far with regard to potential interactions with gut microbiota.
According to this survey, only a minor portion of the 44 medicinal plants considered in EMA monographs for the treatment of gastrointestinal diseases has been studied so far with regard to potential interactions with gut microbiota.